Financials
值 202020212022202320242025 TTM 销售/总务/管理费用 11.62 B12.7 B13.68 B14.77 B14.73 B13.79 B 13.72 B 研发 9.4 B13.83 B12.38 B10.87 B10.93 B12.05 B 12.46 B 营业收入 9.65 B19.28 B34.45 B20.82 B8.51 B13.29 B 6.9 B 营业外收入合计 440 M8.4 B1.85 B5.88 B-2.88 B-5.48 B -6.42 B 利息支出,净利息资本化 1.45 B1.29 B1.24 B2.21 B3.09 B2.67 B 2.69 B 营业外收入,不包括利息支出 -340 M2.23 B833 M2.84 B-1.58 B-1.43 B -2.47 B 非经常性收入/支出 -669 M4.88 B-217 M835 M-4.39 B-6.72 B -6.63 B 税前收入 7.5 B24.31 B34.73 B1.06 B8.02 B7.52 B 7.91 B 收益中的权益 —————— — 税收 477 M1.85 B3.33 B-1.11 B-28 M-266 M 384 M 非控股/少数股权 36 M45 M35 M39 M31 M41 M 43 M 税后其他收入/支出 478 M1.57 B-758 M3.49 B2.26 B470 M 603 M 终止经营前净收入 6.99 B22.41 B31.37 B2.13 B8.02 B7.75 B 7.48 B 已终止经营 2.63 B-434 M6 M-15 M11 M25 M 12 M 净利润 9.62 B21.98 B31.37 B2.12 B8.03 B7.77 B 7.49 B 稀释调整 00———— — 优先股息 00———— — 普通股股东可获得的稀释净收益 9.62 B21.98 B31.37 B2.12 B8.03 B7.77 B 7.49 B 每股基本收益(基本 EPS) 1.733.925.590.381.421.37 1.32 稀释每股收益(稀释 EPS) 1.713.855.470.371.411.36 1.31 平均流通基本股 5.55 B5.6 B5.61 B5.64 B5.66 B5.68 B — 稀释流通股 5.63 B5.71 B5.73 B5.71 B5.7 B5.71 B — 息税折旧摊销前利润 —24.84 B39.97 B27.11 B16.72 B19.88 B 13.48 B 息税前利润 9.65 B19.28 B34.45 B20.82 B8.51 B13.29 B 6.9 B 营业成本 8.69 B30.82 B34.34 B24.95 B17.85 B16.07 B 16.77 B 其他销售成本 ———6.2 B00 — 折旧摊销(现金流) —5.19 B5.06 B6.29 B7.01 B6.59 B 6.59 B
新闻
摩根士丹利基于积极试验数据重申辉瑞制药评级
IP Group 2025财年业绩:净资产值增长13%,辉瑞制药特许权使用费估值1.28亿英镑
辉瑞制药atirmociclib显示癌症进展风险降低40%
葛兰素史克(GSK.US)RSV疫苗获FDA扩大批准 新增2100万成人市场迎战辉瑞竞争
Barclays重申对BridgeBio Pharma股票的增持评级
William Blair首次覆盖BridgeBio股票,给予跑赢大盘评级
BMO重申辉瑞制药股票跑赢大盘评级,基于抗体数据
Ipsen撤回药物后Wolfe Research重申ORIC股票同业表现评级
Hims & Hers股价盘前飙升;辉瑞制药、安捷伦科技下跌
辉瑞制药皮肤病药物试验结果积极,股价仍下跌
辉瑞tilrekimig在皮炎二期试验中达到主要终点
图表与思路
PFE - Daily Trading Forecast
Daily price was bounced from support level at 25.19 to above for 200 SMA to be crossed for the bullish trend to be resumed. Stochastic oscillator is showing the oversold market condition for the price, and Parabolic SAR is on uptrend for the price to be started so the bullish trend continuation is very likely for D1 price for example. if the price breaks 26.54 resistance level to above for the 27.85 possible target so the primary bullish trend will be resumed; If the price crosses support level at 25.19 to below so the bearish reversal will be started with 24.83 as the target to re-enter; alternatively, the price will be on secondary ranging to be near 200 SMA waiting for the direction of the strong trend to be started. Trading Summary : ranging for direction
1 The PFE doesn’t have other trading ideas at this time
Browse ready-made trading ideas or select a symbol and create your own
Go to Charts and Trading Ideas